CEO Robert W. Beck reported strong performance for RM, with a 3.9% revenue increase to $146.34 million in Q3 2024 and a projected 6.6% rise for the year. UBS also showed growth, with a 5.5% revenue increase to $12.33 billion in the same quarter, and expectations of a 15.8% annual rise. Both companies exhibit strong investment potential, reflected in their respective POWR Ratings.
Regeneron Pharmaceuticals is set to report its Q3 earnings on October 31, with analysts expecting a profit of $9.97 per share, a slight decline from the previous year. The stock has risen 14.8% year-to-date, though it lags behind the S&P 500's 22.5% gain. Despite a recent downgrade, the consensus remains bullish, with 18 out of 25 analysts recommending a "Strong Buy."
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.